Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1782, Issue 12, 2008, Pages 795-799

  Rajan, Vik ^a   Mitch, William E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

14 kDa actin fragment; Caspase 3; Chronic kidney disease (CKD); Muscle wasting; Protein degradation; Ubiquitin proteasome system (UPS)

Indexed keywords

ANGIOTENSIN II; CASPASE 3; GLUCOCORTICOID; MUSCLE PROTEIN; MYOSIN ADENOSINE TRIPHOSPHATASE; PROTEASOME; TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

ACIDOSIS; CATABOLISM; CHRONIC KIDNEY DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROXIMAL KIDNEY TUBULAR CELL HYPERTROPHY; REVIEW;

ANIMALS; HUMANS; KIDNEY DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 56449118749     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.07.007     Document Type: Review

References (61)

1. Bailey J.L., Wang X., England B.K., Price S.R., Ding X., and Mitch W.E. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent, ubiquitin-proteasome pathway. J. Clin. Invest. 97 (1996) 1447
2. Baumeister W., Walz J., Zuhl F., and Seemuller E. The proteasome: paradigm of a self-comparmentalizing protease. Cell 92 (1998) 367
3. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clark B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuel D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., and Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Sci. 294 (2001) 1704
4. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., and Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3 (2001) 1014
5. Brink M., Price S.R., Chrast J., Bailey J.L., Anwar A., Mitch W.E., and Delafontaine P. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down regulation of autocrine insulin-like growth factor-1. Endocrin. 142 (2001) 1489
6. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., Hasselgren P.O., Frontera W.R., Lee J., Glass D.J., and Shoelson S.E. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119 (2004) 285
7. Clark A.S., Kelly R.A., and Mitch W.E. Systemic response to thermal injury in rats: Increased protein degradation and altered glucose utilization in muscle. J. Clin. Invest. 74 (1984) 888
8. Clarke B.A., Drujan D., Willis M.S., Murphy L.O., Corpina R.A., Burova E., Rakhilin S.V., Stitt T.N., Patterson C., Latres E., and Glass D.J. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6 (2007) 376
9. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kid. Dis. 41 (2003) 1
10. Dardevet D.D., Sornet C., Taillandier D., Savary I., Attaix D., and Grizard J. Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats: Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J. Clin. Invest. 96 (1995) 2113
11. DeFronzo R.A., and Beckles A.D. Glucose intolerance following chronic metabolic acidosis in man. Am. J. Physiol. 236 (1979) E328-E334
12. Du J., Wang X., Meireles C.L., Bailey J.L., Debigare R., Zheng B., Price S.R., and Mitch W.E. Activation of caspase 3 is an initial step triggering muscle proteolysis in catabolic conditions. J. Clin. Invest 113 (2004) 115
13. Franch H.A., Curtis P.V., and Mitch W.E. Mechanisms of renal tubular cell hypertrophy: Mitogen-induced suppression of proteolysis. Am. J. Physiol. 273 (1997) C843-C851
14. Goodship T.H.J., Mitch W.E., Hoerr R.A., Wagner D.A., Steinman T.I., and Young V.R. Adaptation to low-protein diets in renal failure: leucine turnover and nitrogen balance. J. Am. Soc. Nephrol. 1 (1990) 66
15. Graham K.A., Reaich D., Channon S.M., Downie S., Gilmour E., Passlick-Deetjen J., and Goodship T.H.J. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int. 49 (1996) 1396
16. Graham K.A., Reaich D., Channon S.M., Downie S., and Goodship T.H.J. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J. Am. Soc. Nephrol. 8 (1997) 632
17. Haase V.H., Glickman J.N., Socolovsky M., and Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1583
18. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spielgelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a- and obesity-induced insulin resistance. Sci. 271 (1996) 665
19. Jensen T.J., Loo M.A., Pind S., Williams D.B., Goldberg A.L., and Riordan J.R. Multiple proteolytic systems, including the proteasome contribute CFTR processing. Cell 83 (1995) 129
20. Jentsch S. The ubiquitin-conjugation system. Annu. Rev. Genet. 26 (1992) 179
21. Jurkovitz C., England B.K., Ebb R.G., and Mitch W.E. Influence of ammonia and pH on protein and amino acid metabolism in LLC-PK1 cells. Kidney Int. 42 (1992) 595
22. Kaysen G.A., Dubin J.A., Muller H.G., Rosales L., Levin N.W., and Mitch W.E. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int. 65 (2004) 1408
23. Kimmel P.L., Phillips T.M., Simmens S.J., Peterson R.A., Weihs K.L., Alleyne S., Cruz I., Yanovski J.A., and Veis J.H. Immunologic function and survival in hemodialysis patients. Kidney Int. 54 (1998) 236
24. Kobayashi S., Maesato K., Moriya H., Ohtake T., and Ikeda T. Insulin resistance in patients with chronic kidney disease. Am. J. Kid. Dis. 45 (2005) 275
25. Kopple J.D. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am. J. Kid. Dis. 37 (2001) S66-S70
26. Lecker S.H., Goldberg A.L., and Mitch W.E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 17 (2006) 1807
27. Lecker S.H., Jagoe R.T., Gomes M., Baracos V., Bailey J.L., Price S.R., Mitch W.E., and Goldberg A.L. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18 (2004) 39
28. Lee S.W., Dai G., Hu Z., Wang X., Du J., and Mitch W.E. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J. Am. Soc. Nephrol. 15 (2004) 1537
29. Malik B., Schlanger L., Al-Khalili O., Bao H.F., Yue G., Price S.R., Mitch W.E., and Eaton D.C. ENaC degradation in A6 cells by the ubiquitin-proteasome proteolytic pathway. J. Biol. Chem. 276 (2001) 12903
30. Malik B., Yue Q., Yue G., Chen X.J., Price S.R., Mitch W.E., and Eaton D.C. Role of Nedd4-2 and polyubiquitination in epithelial sodium channel degradation in untransfected renal A6 cells expressing endogenous ENaC subunits. Am. J. Physiol. Renal Physiol. 289 (2005) F107-F116
31. Mansoor O., Beaufrere Y., Boirie Y., Ralliere C., Taillandier D., Aurousseau E., Schoeffler P., Arnal M., and Attaix D. Increased mRNA levels for components of the lysosomal, Ca++-activated and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2714
32. May R.C., Kelly R.A., and Mitch W.E. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J. Clin. Invest. 77 (1986) 614
33. May R.C., Kelly R.A., and Mitch W.E. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: the influence of metabolic acidosis. J. Clin. Invest. 79 (1987) 1099
34. Mitch W.E. Malnutrition: a frequent misdiagnosis for hemodialysis patients. J. Clin. Invest. 110 (2002) 437
35. Mitch W.E., Bailey J.L., Wang X., Jurkovitz C., Newby D., and Price S.R. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Amer. J. Physiol. 276 (1999) C1132-C1138
36. Mitch W.E., and Goldberg A.L. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome system. N. Engl. J. Med. 335 (1996) 1897
37. Pickering W.P., Price S.R., Bircher G., Marinovic A.C., Mitch W.E., and Walls J. Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int. 61 (2002) 1286
38. Price S.R., Bailey J.L., Wang X., Jurkovitz C., England B.K., Ding X., Phillips L.S., and Mitch W.E. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome pathway by a mechanism including gene transcription. J. Clin. Invest. 98 (1996) 1703
39. Price S.R., England B.K., Bailey J.L., Van Vreede K., and Mitch W.E. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am. J. Physiol. 267 (1994) C955-C960
40. Reaich D., Channon S.M., Scrimgeour C.M., Daley S.E., Wilkinson R., and Goodship T.H.J. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am. J. Physiol. 265 (1993) E230-E235
41. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., and Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell 78 (1994) 761
42. Sacheck J.M., Ohtsuka A., McLary S.C., and Goldberg A.L. IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol 287 (2004) E591-E601
43. Salvesen G.S., and Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell 91 (1997) 443
44. Sandri M., Sandri C., Gilbert A., Skuck C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S.H., and Goldberg A.L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004) 399
45. Schnell J.D., and Hicke L. Non-traditional functions of ubiquitin and ubiquitin-binding proteins. J. Biol. Chem. 278 (2003) 35857
46. Solomon V., and Goldberg A.L. Importance of the ATP-ubiquitin-proteasome pathway in degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J. Biol. Chem. 271 (1996) 26690
47. Song Y.H., Li Y., Du J., Mitch W.E., Rosenthal N., and Delafontaine P. Muscle-specific expression of insulin-like growth factor-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 115 (2005) 451
48. Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., and Jogestrand T. Strong association between malnutrition, inflammation and atherosclerosis in chronic kidney failure. Kidney Int. 55 (1999) 1899
49. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Klinenber J.R., Gonzalez M., Yancopoulos G.D., and Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14 (2004) 395
50. Tan R., He W., Lin X., Kiss L.P., and Liu Y. Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication. Am. J. Physiol. Renal Physiol. 294 (2008) F1076-F1083
51. Tawa N.E., Odessey R., and Goldberg A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 100 (1997) 197
52. Tiao G., Fagan J., Roegner V., Lieberman M., Wang J.J., Fischer J.E., and Hasselgren P.O. Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Invest. 97 (1996) 339
53. Tiao G., Hobler S., Wang J.J., Meyer T.A., Luchette F.A., Fischer J.E., and Hasselgren P.O. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Invest. 99 (1997) 163
54. Tidball J.G., and Spencer M.J. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J. Physiol. 545 (2002) 819
55. Tran H., Brunet A., Griffith E.C., and Greenberg M.E. The many forks in FOXO's road. Sci. STKE 2003 (2003) RE5
56. Wang X.H., Hu Z., Hu J.P., Du J., and Mitch W.E. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrin. 147 (2006) 4160
57. Wei W., Fareed M.U., Evenson A., Menconi M.J., Yang H., Petkova V., and Hasselgren P.O. Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R580-R590
58. Williams A.B., Sun X., Fischer J.E., and Hasselgren P.O. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126 (1999) 744
59. Wing S.S., and Goldberg A.L. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am. J. Physiol. 264 (1993) E668-E676
60. Workeneh B., Rondon-Berrios H., Zhang L., Hu Z., Ayehu G., Ferrando A., Kopple J.D., Wang H., Storer T.W., Fournier M., Lee S.W., Du J., and Mitch W.E. Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J. Am. Soc. Nephrol. 17 (2006) 3233
61. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., Lecker S.H., and Goldberg A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 6 (2007) 472